Cargando…
AAV1.NT-3 gene therapy in a CMT2D model: phenotypic improvements in Gars(P278KY/+) mice
Glycyl–tRNA synthetase mutations are associated to the Charcot–Marie–Tooth disease type-2D. The Gars(P278KY/+) model for Charcot–Marie–Tooth disease type-2D is known best for its early onset severe neuropathic phenotype with findings including reduced axon size, slow conduction velocities and abnorm...
Autores principales: | Ozes, Burcak, Moss, Kyle, Myers, Morgan, Ridgley, Alicia, Chen, Lei, Murrey, Darren, Sahenk, Zarife |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568849/ https://www.ncbi.nlm.nih.gov/pubmed/34755111 http://dx.doi.org/10.1093/braincomms/fcab252 |
Ejemplares similares
-
AAV1.NT-3 gene therapy prevents age-related sarcopenia
por: Ozes, Burcak, et al.
Publicado: (2023) -
AAV1.NT‐3 gene therapy in the SOD1KO mouse model of accelerated sarcopenia
por: Tong, Lingying, et al.
Publicado: (2023) -
AAV1.NT-3 gene therapy for X-linked Charcot–Marie–Tooth neuropathy type 1
por: Ozes, Burcak, et al.
Publicado: (2021) -
Systemic delivery of AAVrh74.tMCK.hCAPN3 rescues the phenotype in a mouse model for LGMD2A/R1
por: Sahenk, Zarife, et al.
Publicado: (2021) -
AAV1.NT-3 Gene Therapy for Charcot–Marie–Tooth Neuropathy
por: Sahenk, Zarife, et al.
Publicado: (2014)